Design Therapeutics, Inc. (DSGN)

NASDAQ: DSGN · Delayed Price · USD
11.21
-1.21 (-9.71%)
At close: Jan 21, 2022 3:59 PM
11.23
0.03 (0.22%)
After-hours:Jan 21, 2022 4:00 PM EST
Market Cap623.70M
Revenue (ttm)226,000
Net Income (ttm)-28.32M
Shares Out55.66M
EPS (ttm)-0.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume163,743
Open12.00
Previous Close12.41
Day's Range10.89 - 12.00
52-Week Range10.89 - 43.00
Betan/a
AnalystsBuy
Price Target39.00 (+248.1%)
Earnings Daten/a

About DSGN

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.

IndustryBiotechnology
IPO DateMar 26, 2021
Employees33
Stock ExchangeNASDAQ
Ticker SymbolDSGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for DSGN stock is "Buy." The 12-month stock price forecast is 39.00, which is an increase of 248.06% from the latest price.

Price Target
$39.00
(248.06% upside)
Analyst Consensus: Buy

News

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar has caution about the Company's lead indication of Friedrei...

2 days ago - Benzinga

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Clinical Initiation of Lead GeneTAC TM Program for Friedreich Ataxia On-track for the First Half of 2022

2 months ago - GlobeNewsWire

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 Gen...

Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference

4 months ago - GlobeNewsWire

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022

5 months ago - GlobeNewsWire

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...

7 months ago - GlobeNewsWire

Design Therapeutics Expands Board of Directors with Key Appointments

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...

7 months ago - GlobeNewsWire

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development

8 months ago - GlobeNewsWire

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...

9 months ago - GlobeNewsWire

Design Therapeutics Announces Pricing of Initial Public Offering

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...

9 months ago - GlobeNewsWire

Design Therapeutics sets IPO terms, to be valued at more than $1 billion

Design Therapeutics Inc. has set terms for its initial public offering, in which the California-based biopharmaceutical company focused on gene targeted chimeras (GeneTAC) expects to raise up to $240 mi...

9 months ago - Market Watch